Overview of comments received on guideline on clinical investigation of medicinal products in the treatment of epileptic disorders (CHMP/EWP/566/98 Rev.3)

Submitted by Anonymous (not verified) on 28 April 2025 - 12:32

Overview of comments received on guideline on clinical investigation of medicinal products in the treatment of epileptic disorders (CHMP/EWP/566/98 Rev.3)

Human medicines European public assessment report (EPAR): Twynsta, telmisartan,amlodipine, Date of authorisation: 07/10/2010, Revision: 15, Status: Authorised

Submitted by Anonymous (not verified) on 28 April 2025 - 11:38

Human medicines European public assessment report (EPAR): Twynsta, telmisartan,amlodipine, Date of authorisation: 07/10/2010, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Date of authorisation: 22/11/2018, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 25 April 2025 - 16:30

Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Date of authorisation: 22/11/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Date of authorisation: 18/11/2015, Revision: 15, Status: Authorised

Submitted by Anonymous (not verified) on 25 April 2025 - 15:40

Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Date of authorisation: 18/11/2015, Revision: 15, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness